Unknown

Dataset Information

0

Reversible antibiotic tolerance induced in Staphylococcus aureus by concurrent drug exposure.


ABSTRACT:

Unlabelled

Resistance of Staphylococcus aureus to beta-lactam antibiotics has led to increasing use of the glycopeptide antibiotic vancomycin as a life-saving treatment for major S. aureus infections. Coinfection by an unrelated bacterial species may necessitate concurrent treatment with a second antibiotic that targets the coinfecting pathogen. While investigating factors that affect bacterial antibiotic sensitivity, we discovered that susceptibility of S. aureus to vancomycin is reduced by concurrent exposure to colistin, a cationic peptide antimicrobial employed to treat infections by Gram-negative pathogens. We show that colistin-induced vancomycin tolerance persists only as long as the inducer is present and is accompanied by gene expression changes similar to those resulting from mutations that produce stably inherited reduction of vancomycin sensitivity (vancomycin-intermediate S. aureus [VISA] strains). As colistin-induced vancomycin tolerance is reversible, it may not be detected by routine sensitivity testing and may be responsible for treatment failure at vancomycin doses expected to be clinically effective based on such routine testing.

Importance

Commonly, antibiotic resistance is associated with permanent genetic changes, such as point mutations or acquisition of resistance genes. We show that phenotypic resistance can arise where changes in gene expression result in tolerance to an antibiotic without any accompanying genetic changes. Specifically, methicillin-resistant Staphylococcus aureus (MRSA) behaves like vancomycin-intermediate S. aureus (VISA) upon exposure to colistin, which is currently used against infections by Gram-negative bacteria. Vancomycin is a last-resort drug for treatment of serious S. aureus infections, and VISA is associated with poor clinical prognosis. Phenotypic and reversible resistance will not be revealed by standard susceptibility testing and may underlie treatment failure.

SUBMITTER: Haaber J 

PROVIDER: S-EPMC4313918 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

2020-03-25 | GSE139659 | GEO
2024-07-10 | GSE267626 | GEO
| S-EPMC7198484 | biostudies-literature
| S-EPMC9018823 | biostudies-literature
| S-EPMC11306626 | biostudies-literature
| S-EPMC9952555 | biostudies-literature
| S-EPMC9774800 | biostudies-literature
| S-EPMC10592767 | biostudies-literature
| S-EPMC10543182 | biostudies-literature
2024-07-11 | PXD052440 | Pride